The New York Times @nytimes
People who received a Johnson & Johnson coronavirus vaccine may be better off with a booster from Moderna or Pfizer, according to early data from a U.S. clinical trial. FDA advisers will discuss the findings on Friday. https://t.co/o5aD9DEW1X — PolitiTweet.org